Research
Hormonal
Insulin resistance causes dyslipidemia characterized by high triglycerides, low HDL, and small dense LDL, which significantly increases the incidence of cardiovascular disease.
Insulin resistance changes your lipid profile in a dangerous way: high triglycerides, low HDL, and small dense LDL. This specific combination is highly atherogenic. Managing insulin sensitivity is key to improving this profile.
GoodSupportsHIGH confidence
The dyslipidemia induced by insulin resistance and type 2 diabetes (diabetic dyslipidemia) is characterized by the lipid triad: (1) high levels of plasma triglycerides, (2) low levels of HDL, and (3) the appearance of small dense low-density lipoproteins (sdLDL)... Hypertriglyceridemia increases the incidence of CVD by 32% in men and 76% in women.
Why this rating
Supported by multiple studies and meta-analyses cited in the review.
Source
Association between insulin resistance and the development of cardiovascular disease
Valeska Ormazábal et al. · Cardiovascular Diabetology · 2018
DOI 10.1186/s12933-018-0762-4
narrative_reviewCited 2,367×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance directly causes cardiovascular disease through three primary mechanisms: signal transduction alteration, impaired substrate metabolism regulation, and altered substrate delivery to the myocardium.Good
- Insulin resistance leads to endothelial dysfunction by selectively impairing nitric oxide (NO) production while activating pro-inflammatory and pro-thrombotic pathways, contributing to hypertension and atherosclerosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →